Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability

Cognitive symptoms of schizophrenia are reported to be minimally responsive to treatment with antipsychotic medications, though variability exists and many prior studies have significant confounds. Here, we examined the response of cognitive symptoms to antipsychotic medications in 71 inpatients wit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rachael K. Blackman, Dwight Dickinson, Daniel P. Eisenberg, Michael D. Gregory, José A. Apud, Karen F. Berman
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Psychosis Cognition Antipsychotic treatment Genetics Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b0736ae187b74af2aecddd7097b75af4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b0736ae187b74af2aecddd7097b75af4
record_format	dspace
spelling	oai:doaj.org-article:b0736ae187b74af2aecddd7097b75af42021-11-12T04:35:21ZAntipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability2215-001310.1016/j.scog.2021.100223https://doaj.org/article/b0736ae187b74af2aecddd7097b75af42022-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2215001321000305https://doaj.org/toc/2215-0013Cognitive symptoms of schizophrenia are reported to be minimally responsive to treatment with antipsychotic medications, though variability exists and many prior studies have significant confounds. Here, we examined the response of cognitive symptoms to antipsychotic medications in 71 inpatients with schizophrenia on and off antipsychotic medications in a blinded, placebo-controlled, cross-over study design. Patients received either antipsychotic medication monotherapy or placebo for 4–6 weeks before switching conditions. Neuropsychological testing, including working memory, intelligence, episodic memory, and verbal fluency tests, was administered during each condition. Additionally, we assessed whether polygenic scores for cognitive ability (PGScog) related to variability in antipsychotic medication-induced changes in cognitive performance. Overall, significant changes in cognition were not observed in response to medications (p's > 0.05) except for in episodic memory (p = 0.01), which showed a medication-related improvement. Some antipsychotic medication-related cognitive changes were associated with genetic predisposition to cognitive ability: PGScog showed positive correlations with medication-induced improvements in verbal list learning (p = 0.02) and category fluency (p = 0.03). Our primary results reinforce the notion that in general, cognitive measures are minimally responsive to antipsychotic medication. However, PGScog results suggest that genetic variation may influence the ability of current treatments to affect cognitive change within this patient population. This study underscores the need for development of novel treatment options specifically targeting cognitive symptoms as well as the importance of genetic variability in treatment response for patients with schizophrenia.Rachael K. BlackmanDwight DickinsonDaniel P. EisenbergMichael D. GregoryJosé A. ApudKaren F. BermanElsevierarticlePsychosisCognitionAntipsychotic treatmentGeneticsNeurology. Diseases of the nervous systemRC346-429ENSchizophrenia Research: Cognition, Vol 27, Iss , Pp 100223- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psychosis Cognition Antipsychotic treatment Genetics Neurology. Diseases of the nervous system RC346-429
spellingShingle	Psychosis Cognition Antipsychotic treatment Genetics Neurology. Diseases of the nervous system RC346-429 Rachael K. Blackman Dwight Dickinson Daniel P. Eisenberg Michael D. Gregory José A. Apud Karen F. Berman Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
description	Cognitive symptoms of schizophrenia are reported to be minimally responsive to treatment with antipsychotic medications, though variability exists and many prior studies have significant confounds. Here, we examined the response of cognitive symptoms to antipsychotic medications in 71 inpatients with schizophrenia on and off antipsychotic medications in a blinded, placebo-controlled, cross-over study design. Patients received either antipsychotic medication monotherapy or placebo for 4–6 weeks before switching conditions. Neuropsychological testing, including working memory, intelligence, episodic memory, and verbal fluency tests, was administered during each condition. Additionally, we assessed whether polygenic scores for cognitive ability (PGScog) related to variability in antipsychotic medication-induced changes in cognitive performance. Overall, significant changes in cognition were not observed in response to medications (p's > 0.05) except for in episodic memory (p = 0.01), which showed a medication-related improvement. Some antipsychotic medication-related cognitive changes were associated with genetic predisposition to cognitive ability: PGScog showed positive correlations with medication-induced improvements in verbal list learning (p = 0.02) and category fluency (p = 0.03). Our primary results reinforce the notion that in general, cognitive measures are minimally responsive to antipsychotic medication. However, PGScog results suggest that genetic variation may influence the ability of current treatments to affect cognitive change within this patient population. This study underscores the need for development of novel treatment options specifically targeting cognitive symptoms as well as the importance of genetic variability in treatment response for patients with schizophrenia.
format	article
author	Rachael K. Blackman Dwight Dickinson Daniel P. Eisenberg Michael D. Gregory José A. Apud Karen F. Berman
author_facet	Rachael K. Blackman Dwight Dickinson Daniel P. Eisenberg Michael D. Gregory José A. Apud Karen F. Berman
author_sort	Rachael K. Blackman
title	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
title_short	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
title_full	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
title_fullStr	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
title_full_unstemmed	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
title_sort	antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/b0736ae187b74af2aecddd7097b75af4
work_keys_str_mv	AT rachaelkblackman antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability AT dwightdickinson antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability AT danielpeisenberg antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability AT michaeldgregory antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability AT joseaapud antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability AT karenfberman antipsychoticmedicationmediatedcognitivechangeinschizophreniaandpolygenicscoreforcognitiveability
_version_	1718431252455882752

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability

Ejemplares similares